Unichem Laboratories Limited (UNICHEMLAB.BO)
INR 587.6
(-2.16%)
INR 587.6
(-2.16%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 8.06 Billion INR | 6.49% |
| 2022 | 7.57 Billion INR | 8.19% |
| 2021 | 7 Billion INR | 23.11% |
| 2020 | 5.68 Billion INR | -7.26% |
| 2019 | 6.13 Billion INR | 15.8% |
| 2018 | 5.29 Billion INR | 3.14% |
| 2017 | 5.13 Billion INR | 10.92% |
| 2016 | 4.63 Billion INR | 40.58% |
| 2015 | 3.29 Billion INR | 17.94% |
| 2014 | 2.79 Billion INR | -14.87% |
| 2013 | 3.28 Billion INR | -5.03% |
| 2012 | 3.45 Billion INR | 5.97% |
| 2011 | 3.25 Billion INR | 23.66% |
| 2010 | 2.63 Billion INR | 11.78% |
| 2009 | 2.35 Billion INR | 7.97% |
| 2008 | 2.18 Billion INR | 14.09% |
| 2007 | 1.91 Billion INR | 7.26% |
| 2006 | 1.78 Billion INR | 10.1% |
| 2005 | 1.62 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -23.62 Billion INR | -392.77% |
| 2023 Q2 | 6.61 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q4 | 8.06 Billion INR | 0.0% |
| 2023 FY | 8.06 Billion INR | 6.49% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q4 | 7.57 Billion INR | 0.0% |
| 2022 FY | 7.57 Billion INR | 8.19% |
| 2022 Q2 | 6.18 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2021 Q2 | 6.33 Billion INR | 0.0% |
| 2021 FY | 7 Billion INR | 23.11% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 7 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q2 | 6.07 Billion INR | 0.0% |
| 2020 FY | 5.68 Billion INR | -7.26% |
| 2020 Q4 | 5.68 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q4 | 6.13 Billion INR | 0.0% |
| 2019 FY | 6.13 Billion INR | 15.8% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 5.27 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2018 FY | 5.29 Billion INR | 3.14% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q4 | 5.29 Billion INR | 0.0% |
| 2017 Q3 | 7.07 Billion INR | 0.0% |
| 2017 FY | 5.13 Billion INR | 10.92% |
| 2017 Q4 | 5.13 Billion INR | -27.37% |
| 2016 Q4 | 4.63 Billion INR | 0.0% |
| 2016 FY | 4.63 Billion INR | 40.58% |
| 2015 FY | 3.29 Billion INR | 17.94% |
| 2014 FY | 2.79 Billion INR | -14.87% |
| 2013 FY | 3.28 Billion INR | -5.03% |
| 2012 FY | 3.45 Billion INR | 5.97% |
| 2011 FY | 3.25 Billion INR | 23.66% |
| 2010 FY | 2.63 Billion INR | 11.78% |
| 2009 FY | 2.35 Billion INR | 7.97% |
| 2008 FY | 2.18 Billion INR | 14.09% |
| 2007 FY | 1.91 Billion INR | 7.26% |
| 2006 FY | 1.78 Billion INR | 10.1% |
| 2005 FY | 1.62 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | 50.416% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 94.699% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -55.75% |
| Granules India Limited | 22.95 Billion INR | 64.847% |
| Indoco Remedies Limited | 10.34 Billion INR | 21.978% |
| Achyut Healthcare Limited | 2.01 Million INR | -400757.079% |
| Ajanta Pharma Limited | 10.71 Billion INR | 24.659% |
| Alkem Laboratories Limited | 48.6 Billion INR | 83.398% |
| Alpa Laboratories Limited | 307.12 Million INR | -2527.377% |
| Brooks Laboratories Limited | 248.6 Million INR | -3145.865% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -120.405% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -65.772% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -282.637% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 92.456% |
| Eris Lifesciences Limited | 38.26 Billion INR | 78.914% |
| FDC Limited | 3.7 Billion INR | -117.547% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 87.607% |
| Gufic Biosciences Limited | 5.59 Billion INR | -44.099% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -252.452% |
| Ipca Laboratories Limited | 33.74 Billion INR | 76.086% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -2619.117% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -171.334% |
| Lasa Supergenerics Limited | 541.92 Million INR | -1388.998% |
| Laurus Labs Limited | 42.71 Billion INR | 81.109% |
| Lupin Limited | 96.23 Billion INR | 91.615% |
| Mankind Pharma Limited | 23.87 Billion INR | 66.202% |
| Medicamen Biotech Limited | 940.36 Million INR | -758.096% |
| Medico Remedies Limited | 438.24 Million INR | -1741.269% |
| Megasoft Limited | 1.85 Billion INR | -335.436% |
| NATCO Pharma Limited | 10.53 Billion INR | 23.383% |
| Piramal Pharma Limited | 74 Billion INR | 89.096% |
| RPG Life Sciences Limited | 1.38 Billion INR | -484.644% |
| Sigachi Industries Limited | 2.53 Billion INR | -218.783% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 95.604% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -296.674% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -592.514% |
| Wanbury Limited | 3.15 Billion INR | -155.719% |
| Windlas Biotech Limited | 1.76 Billion INR | -357.778% |
| ZIM Laboratories Limited | 2.08 Billion INR | -287.803% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 88.76% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -107.281% |
| Divi's Laboratories Limited | 18.99 Billion INR | 57.508% |
| Hester Biosciences Limited | 3.59 Billion INR | -124.475% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -215.058% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -929.473% |
| Bal Pharma Limited | 2.51 Billion INR | -221.321% |
| Strides Pharma Science Limited | 37.68 Billion INR | 78.585% |
| Venus Remedies Limited | 1.39 Billion INR | -479.355% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | 2.199% |
| Nectar Lifesciences Limited | 11.21 Billion INR | 28.069% |
| Shilpa Medicare Limited | 12.93 Billion INR | 37.605% |
| Aarti Drugs Limited | 11.5 Billion INR | 29.857% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -27.499% |
| Suven Life Sciences Limited | 148.62 Million INR | -5329.416% |
| Ind-Swift Limited | 13.45 Billion INR | 40.019% |
| Valiant Laboratories Limited | 1.05 Billion INR | -662.503% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | 24.643% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | 42.948% |
| Themis Medicare Limited | 1.88 Billion INR | -327.508% |
| Hikal Limited | 12.99 Billion INR | 37.904% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 90.165% |
| Sequent Scientific Limited | 8.27 Billion INR | 2.478% |
| Novartis India Limited | 1.8 Billion INR | -348.018% |
| Wockhardt Limited | 39.87 Billion INR | 79.761% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 86.831% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -2694.072% |
| Neuland Laboratories Limited | 5.49 Billion INR | -46.752% |
| Morepen Laboratories Limited | 4.45 Billion INR | -80.934% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -1153.217% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -308.299% |